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Purpose: Multiple sclerosis (MS) is a long-lasting disabling disease with psychological 
implications. Hospital Anxiety and Depression Scale (HADS) is a questionnaire developed to 
screen anxiety and depression among patients in hospital settings. The objective of this report 
was to study the metric properties of the Portuguese version of HADS regarding MS.
Materials and methods: This was a cross-sectional study. Three hundred and eighty 
individuals with a diagnosis of MS, according to the revised McDonald criteria, were recruited 
from an outpatient Neuroimmunology Clinic of the city of Porto. Participants had a mean age 
of 40.04 years (SD =10.86), 63.9% of them were female. HADS consists of two subscales – 
anxiety and depression – scored separately, with seven items each.
Results: The results of our study show the appropriateness of HADS for the identification of 
mood changes in people with MS and show good metric properties.
Conclusion: It seems to be a useful tool for the scrutiny of mood disorders in Portuguese 
patients with MS. The questionnaire is also sensitive to disease when compared to people with 
other severe illnesses, and with people without the disease.
Keywords: multiple sclerosis, depression, anxiety, HADS
Introduction
Multiple sclerosis (MS) is a chronic disease of the nervous system that produces various 
symptoms and may lead to severe disability with critical psychological implications. 
Population-based studies show that most patients are ambulatory even after many 
years of disease duration.1
The Hospital Anxiety and Depression Scale (HADS) is a brief self-reporting two-
dimensional questionnaire developed to screen for levels of anxiety and depression 
among patients in a general hospital setting.2,3 In a systematic review of the structure 
of the HADS, Cosco et al4 found divergences in the latent structure of the question-
naire and recommends caution because of the apparent lack of consistency between 
studies. This matter led to calls for the abandonment of the HADS.5 In response to 
these conclusions, a meta confirmatory factor analysis (CFA)6 provides support for 
the bifactor model but suggests caution in the use of the scale. Stern7 confirms that 
HADS is appropriate for initial diagnosis and to track the progression of psychological 
symptoms. National Institute for Health and Care Excellence (section 1.3.2, point 
1.3.2.3)8 had recommended the scale for the diagnosis of depression and anxiety.
HADS is one of the most widely used questionnaires among patients with neuro-
logical illnesses, and it is useful for assessing patients who tire easily or have limited 
concentration spans.9 Watson et al10 confirm that HADS is an appropriate screening 
measure for people with MS. Litster et al11 in a systematic review about the assessment 
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of anxiety in people with MS state that HADS-A shows 
promise as an applicable measure for this population. In the 
evaluation of depression in people with MS, a systematic 
review of Hind et al12 asserts that HADS-D is a useful screen-
ing instrument.
However, research alerts about possible problems in the 
translated versions and cross-cultural use of the HADS and 
claims that rates of anxiety and depression using the same cut 
point across languages and culture may be wrong or subject 
to critical scrutiny.13
In a previous study,14 the metric properties of a Portuguese 
version of HADS were described when applied to 1,322 
individuals with chronic diseases, namely, cancer, stroke, 
epilepsy, coronary heart disease, morbid obesity, diabetes, 
myotonic dystrophy, obstructive sleep apnea, depression, and 
a non-disease group.
The core objective of the present report was to describe 
the metric properties of the Portuguese version of HADS 
among people with MS.
Materials and methods
Participants
We analyzed a consecutive sample of 380 individuals 
(63.9% female, 36.1% male; mean age 40.04±10.86 years; 
range: 16–71 years) with MS according to the revised 
McDonald criteria, from the outpatient Neuroimmunology 
Clinic at a Central Hospital in Porto, Portugal.
Measure
haDs
HADS consists of two subscales, one measuring anxiety, 
with seven items, and another measuring depression, 
with seven items, which score separately. Each item was 
answered by the patient on a 4-point (0–3) scale, so the 
possible scores ranged from 0 to 21 for each of the two 
subscales, taking 2–5 minutes to complete.2,3 The HADS 
manual indicates that a score between 0 and 7 is “normal,” 
between 8 and 10 “mild,” between 11 and 14 “moderate,” 
and between 15 and 21 “severe.” Some authors propose a 
different classification. In a study with a Brazilian sample 
(Portuguese-Brazilian language), Botega et al15 proposed a 
cutoff point of 8/9 for anxiety and depression scales. Other 
studies suggest that the recommended cutoff scores for the 
HADS may result in under-reporting of psychiatric morbidity 
in different chronic diseases.16
The original authors post a score of $11 as indicating 
the probable presence (“caseness”) of a mood disorder, and 
a score of 8–10 being just suggestive of the presence of the 
respective state. Based on the score of $8, Honarmand and 
Feinstein’s research17 confirms the usefulness of the HADS 
as a marker of major depression and generalized anxiety 
disorder in MS patients. In a review of different screening 
measures to identify anxiety disorders in MS, Litster et al11 
conclude that HADS is the best available tool for detecting 
the symptoms of anxiety in individuals with MS.
Procedure
The study used a cross-sectional design with all measures 
taken at the same time. Ethical approval for the study was 
given by the ethical committee at the hospital St. Antonio, 
Porto, according to hospital rules and Portuguese law. 
Namely, signed informed consent was obtained before par-
ticipation in the study in accordance with the Declaration of 
Helsinki. A registered psychologist administered the tests 
individually during the patient routine visit to the hospital.
statistical analysis
To identify the factorial structure of the scale, in this group 
of MS patients, exploratory factor analysis was applied. 
Moreover, to test the hypothesized two model dimensions, 
CFA was used.
Results
exploratory factorial validity
Exploratory factor analysis using principal component 
analysis, oblimin rotation method with Kaiser normaliza-
tion for the 14 items, showed two components: the first one 
associated with the seven anxiety items and the second one 
related to the seven items from depression. The total vari-
ance of the solution explains 49.07% (39.26% for the first 
component). Loadings on the component that they belong to 
are in bold format in Table 1. All items load on the dimen-
sion they belong to.
Differences in loadings between the component the item 
belongs to and the component it does not belong to are above 
0.15 points, except for item 14. Table 1 shows loadings 
on the dimensions above 0.35. Internal consistency, using 
Cronbach’s alpha, for the two dimensions is good; 0.80 for 
anxiety and 0.81 for depression.
cFa
CFA is a theory-testing model as opposed to a theory-generating 
method such as exploratory factor analysis. Byrne20 suggests 
that there is a wide array of fit indexes from which to choose, 
but that only one or two needs be reported. Maximum likeli-
hood CFA, using EQS V6.121 was used to test the two-factor 
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hypothesized model. Results show a LISREL goodness-of-fit 
index of 0.90 and a root mean square error of approximation 
(RMSEA) of 0.08 (90% confidence interval of RMSEA, 
between 0.07 and 0.10), a result that suggests an acceptable 
fit of the two dimensions model.22,23 It is similar to other 
reported studies.24
comparison between groups
Independent t-tests were used to compare the anxiety and 
depression subscale scores between MS patients and the 
other disease groups from previous studies with Portuguese 
samples.14 Comparison of the results of the previous study 
and the MS group is presented in Table 2.
HADS mean values obtained in the present study for 
people with MS are higher [anxiety: 7.94 (SD=4.31), 
depression: 5.63 (SD=4.01)] than those reported in other 
studies for both the dimensions,25,26 but lower if compared 
with other studies.27 Correlation between anxiety and depres-
sion are statistically significant [r(380) =0.60]. Correlations 
between age and anxiety are not statistically significant. 
However, correlations between age and depression is sta-
tistically significant [r(375)=0.30, P,0.001], also different 
from the study of Jones et al,27 which did not find statisti-
cally significant correlations between age and depression 
and report a statistically significant correlation between age 
and anxiety.
Differences between gender for anxiety and depres-
sion are statistically significant at the P level ,0.001, with 
females showing higher mean values than males (anxiety 
8.72 vs 6.57 and depression 6.24 vs 4.55). These values are 
different from the ones reported by Jones et al27 which, for 
depression, report higher values in men: these differences 
are also reported in other studies in different languages and 
problems.28
In the present study, for depression, 8.2% of the partici-
pants exhibited a score of $11 and 23.4% a score of $8, 
and for anxiety, 21.6% of the participants presented a score 
of $11 and 41.6% a score of $8. These values are similar to 
those reported by Siegert and Abernethy.29 For depression by 
gender, 9.9% of females exhibit a value of $11 and 28.8% a 
value of $8, and 5.1% of males exhibit a value of $11 and 
15.9% a value of $8. For anxiety, 28.5% of males exhibit a 
value of $8 and 16.1% a value of $11 and 24.7% of females 
exhibit a value of $11 and 49% a value of $8. These scores 
suggests a possible presence of mood disorder for most of 
the sample for anxiety.
When comparing the MS group with other chronic dis-
eases, more statistically significant differences are found 
for depression than for anxiety. For anxiety, no statistically 
Table 1 exploratory factor analysis – presenting loadings above 
0.35
Anxiety Depression
haDs1 0.74 0.39
haDs2  0.78
haDs3 0.75 0.40
haDs4 0.49 0.79
haDs5 0.74 0.40
haDs6 0.53 0.79
haDs7 0.60 0.43
haDs8 0.53
haDs9 0.65 0.43
haDs10 0.35 0.72
haDs11 0.52
haDs12 0.36 0.71
haDs13 0.71 0.44
haDs14 0.46 0.50
Notes: extraction method: principal component analysis. rotation method: oblimin 
with Kaiser normalization. Bold figures represent that the item belongs to that 
factor or dimension in coincidence with the higher loading.
Table 2 Anxiety and depression means by disease group, and statistically significant differences with MS patients
Disease group n Anxiety Depression
M (SD) t P-value M (SD) t P-value
No disease 22 7.81 (4.72) 0.09 0.93 3.22 (3.02) 2.74 ,0.01
cancer 98 9.18 (4.74) -2.59 0.009 5.89 (4.34) -0.57 0.56
stroke 252 10.53 (4.36) -7.50 ,0.001 9.19 (4.63) -10.13 ,0.001
epilepsy 100 8.59 (4.17) -1.45 0.14 5.18 (4.18) 0.97 0.33
Diabetes 316 8.18 (4.53) -0.86 0.39 5.46 (4.34) 0.52 0.60
cardiac coronary disease 274 8.41 (3.86) -1.57 0.11 5.53 (3.99) 0.31 0.75
Morbid obesity 190 10.52 (4.35) -6.85 ,0.001 7.28 (4.35) -4.45 ,0.001
Obstructive sleep apnea 31 6.87 (3.39) 1.31 0.19 3.83 (2.66) 2.42 0.01
Depression 20 11.00 (3.91) -3.18 0.002 12.90 (3.71) -7.87 ,0.001
Myotonic dystrophy 18 7.27 (4.07) 0.61 0.54 7.22 (4.14) -1.63 0.10
Multiple sclerosis 380 7.94 (4.31) – – 5.63 (4.01) – –
Abbreviations: M, mean; Ms, Multiple sclerosis; P, level of statistical significance; t, test for independent samples.
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significant differences were found between the MS group 
and the non-disease group. For depression, statistically 
significant differences [t(390)=2.74, P,0.01] were present, 
showing that the MS group had higher values (M=5.63) than 
the non-disease group (M=3.22). Comparing with the depres-
sion disease group, the magnitude of values is much higher 
for the depression group. These results seem to confirm the 
results of a review by Siegert and Abernethy,29 which states 
that depression is common in MS.
Statistically significant differences were found when 
anxiety and depression scores were compared between MS 
patients and those with other diseases (Table 2). Compared 
with the depression group, MS patients showed statistically 
significant lower values in anxiety [t(388)=3.18, P,0.01] 
and in depression [t(388)=7.87, P,0.001].
Furthermore, similar differences were found in anxiety 
scores in cancer, stroke, and morbid obesity patients, and 
in depression scores in stroke and morbid obesity patients. 
MS patients had significantly higher depression scores than 
obstructive sleep apnea patients.
Correlations between age and anxiety and depression 
show a non-significant association for anxiety and a sta-
tistically significant association – though moderate – for 
depression [r(365)=0.29, P,0.0001], suggesting that age is 
not associated with anxiety and depression. The correlation 
between anxiety and depression [r(380)=0.60, P,0.0001] 
is similar to the Portuguese adaptation study14,19 and other 
reported studies.
Discussion and conclusion
International research on HADS shows that it is a useful 
tool to evaluate anxiety and depression in people suffering 
from different diseases, including MS. In an extensive study, 
Dahl et al30 show that anxiety and depression occur more 
frequently in MS patients than in the general population. 
Because anxiety and depression seem to be common in 
people with MS,17 it seems appropriate to screen for possible 
mood elevation in these patients. Our study identifies, for 
depression, essential differences between people with MS 
and people without diseases, and people with a diagnostic of 
depression and people with MS, suggesting the existence of 
a sensibility that differentiates between people with MS and 
people with and without the diagnosis of depression when 
using HADS dimensions.
The results of our report confirm the findings from inter-
national research and suggest that the Portuguese HADS 
version behaves similarly. It seems to be a useful tool for the 
scrutiny of mood in Portuguese patients with MS as it is for 
other diseases. Remember that in the original development 
of the scale, because scores can be affected by the physical 
illness of the patient, authors eliminated items relating simul-
taneously to emotional disorder and physical disorder. Items 
selected were based solely on the anxiety and depression 
symptoms.3 Because items are independent of the characteris-
tics of the disease, people with different diseases, and people 
without diseases, may have the same level of emotional dis-
turbance, due to some other life events than the ones related 
to the disease (symptoms and inherent treatment). HADS is 
a useful tool to help people in medical settings cope with the 
disease and reduce emotional distress.
The objective of the research was to report the metric 
properties and the dimensionality of HADS because recent 
research suggests for example “No further research needed: 
abandoning the Hospital and Anxiety Depression Scale.”5 
while others suggests a different number of dimensions of the 
scale.4,24,31,32 However, more profound research recommends 
that the two-factor solution seems to be the most appropriate 
solution for HADS6 together with large population studies.18 
Other research suggests that HADS may be challenging to 
translate and that translated versions of the HADS may not 
be attainable.13 However, different languages found that the 
HADS is appropriate for use and found the same factorial 
solution for the HADS.14,33 In the present study, the results 
suggest that the translated version behaves like other different 
languages translations. The psychometric properties are 
good, and a clinimetric analysis shows sensitivity when we 
compare people with different chronic diseases to people 
without any condition. In conclusion, the HADS seems to 
be a useful instrument to be included in the study of people 
with MS.
Disclosure
The authors report no conflicts of interest in this work.
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